

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Toshio Sone et al. Art Unit : 1644
Patent No. : 7,025,964 Examiner : P. Huynh
Issue Date : April 11, 2006
Serial No. : 09/308,027
Filed : August 16, 1999
Title : PEPTIDE-BASED IMMUNOTHERAPEUTIC AGENT

Attn.: Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF REQUEST TO CORRECT CERTIFICATE OF CORRECTION

Applicant hereby requests that the Certificate of Correction issued December 12, 2007 for the above patent be corrected as indicated on the marked-up copy attached herewith and described below:


1. On page one of the Certificate of Correction, in the seventh paragraph from the top that reads "Col. 5, line 6, 'to' should be --of--.", "Col. 5" should be **Col. 6**;
2. On page one of the Certificate of Correction, in the eight paragraph from the top that reads "Col 5, line 7, 'allergy' should be --allergy.--.", "Col. 5" should be **Col. 6**; and
3. On page one of the Certificate of Correction, in the ninth through eleventh paragraphs from the top that read "Col. 5, line 7, 'caused by antigen peptides . . . cryptomeria pollen allergy.--", "Col. 5" should be **Col. 6**.

These errors sought to be corrected were made by applicant. The required fee of 37 CFR §1.20(a) is **\$100**. Please apply this and any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: _____

2/28/07



Stuart Macphail, Ph.D., J.D.
Reg. No. 44,217

Fish & Richardson P.C.
Citigroup Center - 52nd Floor
153 East 53rd Street
New York, New York 10022-4611
Telephone: (212) 765-5070
Facsimile: (212) 258-2291

30319361

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,025,964 B1
APPLICATION NO. : 09/308027
DATED : April 11, 2006
INVENTOR(S) : Akinori Kume et al.

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page, Item 56 References Cited Section - OTHER PUBLICATIONS, line 4: "Japanese" should be --Japanese--.

On the Title Page, Item 57

In the Abstract, lines 1-3: "A peptide-based immunotherapeutic agent effective for every allergy patient is provided. A reagent for typing HLA class II molecules of the patient to be used in selecting a peptide-based immunotherapeutic agent effective for every allergy patient is also provided."

should read as follows:

--Peptide-based immunotherapeutic agents effective for each individual allergy patient are provided. Reagents for typing HLA class II molecules of patients to be used in selecting peptide-based immunotherapeutic agents effective for each individual allergy patient are also provided.--.

Col 5, second paragraph, line 16, "challenge" should be --challenged--.

* Col. 6 ~~Col. 5~~, line 6, "to" should be --of--.

* Col. 6 ~~Col. 5~~, line 7, "allergy" should be --allergy--.

* Col. 6 ~~Col. 5~~, line 7, "caused by antigen peptides presented by HLA-DPB1*0501. HLA-DPB1*0501 is frequently present in patients suffering from Cryptomeria pollen allergy induced by Cry j 1 and Cry j 2, and antigen peptides presented by different HLA class II molecules (DR, DQ or DP) (Japanese Patent Application No. Hei 8-70702)."

should read as follows:

--These multiple-epitope peptides comprise antigen peptides presented by different HLA class II molecules (DR, DQ or DP), and antigen peptides that are derived from both Cry j 1 and Cry j 2 and which are presented by HLA-DPB1*0501 (Japanese Patent Application No. Hei 8-80702). HLA-DPB1*0501 exists at a high frequency in patients suffering from cryptomeria pollen allergy.--

Col. 6, line 4, after "provided" please add --, for example,--.

Col. 6, line 5, "multiple" should be --multi--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,025,964 B1
APPLICATION NO. : 09/308027
DATED : April 11, 2006
INVENTOR(S) : Akinori Kume et al.

Page 2 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 7, line 1, "there is a bias in the use of HLA class II (at the locus level) molecules that is determined by the antigen."

should read as follows:

--, depending on the antigen type, there is a bias towards restriction molecules at the HLA class II locus level, and that this defines immune reactions.--

Col. 8, line 11, "Moreover, if T-cell response can be found in a subject (an allergic-response-positive patient), the type of the subject's HLA class II molecules restricting the antigen peptides that induced the T-cell response can be identified as the HLA class II type endowing susceptibility to said allergen in the subject."

should read as follows:

--For subjects showing a T cell response (allergy response-positive patients), the type of HLA class II restriction molecule for the antigen peptide that induces the T cell response can be identified as the subjects' HLA class II type.--

Col. 8, line 65, "expression of a polypeptide with a peptide composed of"
should read as follows: --expressing, as a polypeptide, a peptide with--.

Col. 9, line 14, "shows the overlapping peptides of Cry j 1 containing epitopes recognized by patient's T-cells"

should read as follows: --shows Cry j 1 overlapping peptide sequences and the patients' T-cell epitope sites.--

Col. 9, line 18, "shows the overlapping peptides of Cry j 2 containing epitopes recognized by patient's T-cells"

should read as follows: --shows Cry j 2 overlapping peptides and the patients' T-cell epitope sites.--

Col. 9, line 39, "shows the immune responses of CB6F1 mouse to Cry j 2 when the antigen peptide p186-200 of Cry j 2 was administered to the mouse."

should read as follows; --shows the immune response of CB6F1 mice to Cry j 2 when the antigen peptide p236-250 of Cry j 2 was administered to the mice.--

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO. : 7,025,964 B1
APPLICATION NO. : 09/308027
DATED : April 11, 2006
INVENTOR(S) : Akinori Kume et al.

Page 3 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 11, line 1, "The number of T-cell epitope sites of Cry j 1 recognized by each patient was 9.8 ± 3.0 on average and ranged from $4 \leq 15$ epitopes."

should read as follows:

—Identification of T-cell epitope sites using T-cell lines recognizing Cry j 1 revealed that the number of T-cell epitope sites recognized by each patient was 9.8 ± 3.0 on average and ranged from $4 \leq 15$ epitopes.—

Col. 12, line 36, "Restriction molecules of each LHA class II type of T-cell clones whose restriction molecules were identified at the locus level can be identified by using as antigen-presenting cells, mouse L-cells transformed with the DR gene and B-cell lines that are homozygous at the DQ or DP loci."

should read as follows:

—Restriction molecules of each HLA class II type of T-cell clones whose restriction molecules were identified at the locus level can be identified by using as antigen-presenting cells, mouse L-cells transformed with the DR gene and B-cell lines having the same DQ or DP haplotype.—

Col. 13, line 7, "(Medojenics)" should be —(MedGenics)—.

Col. 55, Claim 1, line 48, "0501" should be —1501—.

Signed and Sealed this

Twelfth Day of December, 2006



JON W. DUDAS
Director of the United States Patent and Trademark Office

Attorney's Docket No.: 14883-031001
Client's Ref. No.: M1-808PCT-US

OFFICIAL COMMUNICATION FACSIMILE:

OFFICIAL FAX NO: (571) 270-9945

Number of pages including this page

Applicant : Toshio Sone et al.
Patent No.: 7,025,964
Issued : April 11, 2006


Art Unit : 1644
Examiner : P. Huynh

Title : PEPTIDE-BASED IMMUNOTHERAPEUTIC AGENT

Ms. Michelle Williams
Certificates of Correction
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

A Request to Correct Certificate of Correction dated **February 28, 2007** is attached.

Respectfully submitted,


Stuart Macphail, Ph.D., J.D.
Reg. No. 44,217

Date: February 28, 2007

Fish & Richardson P.C.
Citigroup Center
52nd Floor
153 East 53rd Street
New York, New York 10022-4611
Telephone: (212) 765-5070
Fax: (212) 258-2291

30325932

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at (212) 765-5070 to arrange for its return. Thank you.